We report net peptide content, not just purity — so the milligrams you dose aren't padded with water and counter-ion. RP-HPLC purity and ESI-MS identity, on a lot-numbered COA.
Net peptide content, not just purity — RP-HPLC + ESI-MS, lot-numbered COA.
Net peptide content on every lot's COA.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
Lyochem primary owner
This Lyochem page is the primary SEO owner for research labs, CROs, and method-development teams qualifying Bronchogen as a documented research-standard lot. The page should answer whether the buyer can review HPLC purity, identity confirmation, lot continuity, stability handling, and assay-fit documentation before ordering.
Overview
A member of the Khavinson class of short-peptide bioregulators, Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL) directed at respiratory-tissue regulatory pathways. The working hypothesis behind the whole family holds that short, tissue-specific peptide fragments act as endogenous regulators of cell-cycle and gene-expression programs in their target tissue; for Bronchogen, the Russian-school literature positions that target as bronchial epithelium and respiratory-tissue maintenance. Its origin traces to the St. Petersburg Institute of Bioregulation and Gerontology, where it was created as the series' respiratory entry. Its tissue-directed siblings include Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), and Cardiogen (cardiovascular). Lyochem supplies Bronchogen as a lyophilized reference standard in a 20 mg vial at ≥99.0% HPLC purity. CAS registration is inconsistent across suppliers for this bioregulator class, so identity rests on analytical data rather than a catalog number: every batch COA reports LC-MS/MS sequence verification together with ESI-MS confirmation of the AEDL tetrapeptide mass. That explicit sequencing matters here because the family's tetrapeptides (AEDG / AEDL / AEDP / KED) fall close together in mass and cannot be told apart by intact mass alone. Chromatographic purity and residual-water content complete the release specification.
Applications & buyer fit
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
A Khavinson bioregulator of Russian scientific lineage, typically without a registered CAS. Per-batch COA data should confirm both the AEDL sequence and identity; because masses within the family sit close together, telling it apart from sibling tetrapeptides (AEDG / AEDP / KED) is essential.
Selected literature
Frequently asked questions
The Khavinson tetrapeptides share an Ala-Glu-Asp core and differ only in the fourth residue, and their masses fall within a narrow window, so intact-mass measurement cannot reliably tell Bronchogen (AEDL) from Epitalon (AEDG) or Cortagen (AEDP). Sequencing by LC-MS/MS that maps the complete b- and y-ion series is the definitive test, because reading the C-terminal residue directly resolves the ambiguity that a shared-neighbor mass leaves open. RP-HPLC adds a retention-based cross-check against a qualified reference. For any single tetrapeptide from a new source, explicit sequence data on the COA is the appropriate identity requirement.
Beyond identity, the release panel should report RP-HPLC purity, ESI-MS mass, and Karl Fischer water so net peptide content supports accurate molar dosing. For intranasal preparation, dilute into isotonic saline at neutral pH and avoid quaternary-ammonium preservatives such as benzalkonium chloride, which can interact with short peptide sequences and compromise the material. Prepare working dilutions fresh and keep concentrated stock cold to limit degradation between sessions. Recording the COA lot and re-confirming identity by LC-MS/MS if a stock has aged keeps respiratory-tissue readouts traceable to one characterized batch of the tetrapeptide.
Related peptides
Khavinson cardiovascular short-peptide bioregulator
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
3-mer
Khavinson neuroprotective tripeptide (Glu-Asp-Arg, EDR)